Compare DRVN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRVN | NVAX |
|---|---|---|
| Founded | 1972 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2020 | 1996 |
| Metric | DRVN | NVAX |
|---|---|---|
| Price | $10.70 | $10.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 9 |
| Target Price | ★ $19.57 | $11.33 |
| AVG Volume (30 Days) | 2.3M | ★ 4.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 59.82 | ★ 309.76 |
| EPS | 0.69 | ★ 2.58 |
| Revenue | ★ $2,339,588,000.00 | $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | $15.35 | ★ $3.89 |
| Revenue Growth | 1.54 | ★ 64.69 |
| 52 Week Low | $9.80 | $5.01 |
| 52 Week High | $19.74 | $11.85 |
| Indicator | DRVN | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 26.64 | 52.87 |
| Support Level | $9.92 | $7.81 |
| Resistance Level | $15.81 | $10.63 |
| Average True Range (ATR) | 0.46 | 0.66 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 40.95 | 44.95 |
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.